Overview

The China-New Zealand Joint Laboratory on Biomedicine and Health (hereinafter referred to as the Joint Laboratory) was jointly established by the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, and the Maurice Wilkins Centre (MWC) at the University of Auckland, New Zealand. It officially received approval from the Ministry of Science and Technology in August 2021. The Joint Laboratory focuses on frontier research in biomedicine and health, aiming to deepen and expand scientific and technological collaboration. By leveraging the innovative resources and expertise of both institutions, it seeks to enhance the supporting capabilities of research platforms, promote the transfer and commercialization of scientific achievements, and facilitate substantial breakthroughs from basic research to practical application. The laboratory also initiates new models for cultural and technological exchanges, facilitating talent exchanges and training between China and New Zealand.


The management of the joint laboratory is comprised one director and one executive deputy director from each side, with one or two deputy directors. The management committee is consisted of 5-6 members, typically including the laboratory director, executive deputy director, deputy directors, leaders in charge of international cooperation from both institutions, and heads of departments responsible for international collaboration. Additionally, the joint laboratory has an academic secretary and an administrative secretary. The current director of the joint laboratory is Prof. SUN Fei from China and Prof. David R Grattan from New Zealand. The executive deputy director is Prof. LI Peng from China and Dr. Peter Lai from New Zealand.


The initial members of the Joint Laboratory comprise teams that contributed to its early establishment and that have jointly applied for and received approval for national, provincial, and municipal projects alongside the MWC team in New Zealand. As an open platform, the joint laboratory will attract more young scientists to engage in collaborative research with New Zealand in areas such as large-scale scientific research facilities for human cell atlases, cryo-electron microscopy technology, and xenotransplantation.


Research

The Joint Laboratory primarily engages in joint research and clinical translation across five key areas: stem cell and regenerative medicine research, biotherapy for cancer, treatment of metabolic diseases, drug development, and infectious disease prevention and control.


Through joint efforts and collaboration, the China-New Zealand partnership has delivered an impressive array of pivotal achievements. For instance, they have successfully completed a Phase I clinical trial (NCT04049513) for CAR-TLR2 T cell therapy for lymphoma, resulting in no serious adverse events and all patients displaying no neurological toxicity. A Phase II multicenter clinical trial for the automated production of CAR-T cells for lymphoma is currently in progress, with plans to gain approval in New Zealand and Australia by 2026. This initiative represents the first and only clinical study for CAR-T cell therapy targeting malignant tumors introduced in New Zealand. And the LX-132 Capsule, a novel targeted anti-cancer drug jointly developed by China and MWC, has obtained clinical approval as a Class I new drug. Following nearly a decade of research and development, clinical trials in China are imminent, with an anticipated market launch in 2028. This groundbreaking medication holds promise as a new option and beacon of hope for patients experiencing resistance to first-generation reversible drugs. Recently, it has been demonstrated that a Chinese pharmaceutical therapy containing TB47 can cure multidrug-resistant tuberculosis within a span of 2 to 3 months, potentially reducing the treatment duration by half compared to the shortest existing therapy currently available. The newly developed drug, TB47, has successfully obtained Investigational New Drug (IND) application acceptance.


In terms of jointly cultivating talent between China and New Zealand, the joint laboratory, established as an open platform for scientific research collaboration, has sparked numerous promising new avenues for cooperation through numerous visits and exchanges. These encompass large-scale scientific research facilities for human cell lineage studies, cryo-electron microscopy technology, and xenotransplantation, all of which have garnered mutual interest from both China and New Zealand.


Resources

The advantages of New Zealand's biopharmaceutical industry mainly lie in the high efficiency of new drug clinical trial approvals, alignment of clinical trials with international standards, unique biological resources, and advanced equipment and software supplies. These factors above provide crucial support for the rapid development of New Zealand's biopharmaceutical sector. By co-establishing a joint laboratory, we can leverage these new resources to facilitate the conversion and implementation of our biomedicine achievements and to move towards internationalization.

In terms of talent development, on October 18, 2023, the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, signed a joint doctoral training agreement with the University of Auckland. The agreement outlines a dual-supervisor model and adopts a "3+1" training format, with the doctoral degree awarded by the University of Auckland.


History

During President Xi visit to New Zealand from November 19th to 21st, 2014, China and New Zealand jointly signed and renewed 25 science and technology cooperation agreements. Among them, the academic exchange and cooperation agreement signed between the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, and the Maurice Wilkins Centre at the University of Auckland was the only agreement in the field of population health. In the same year, Bai Chunli, President of the Chinese Academy of Sciences, visited the University of Auckland and witnessed the signing of a comprehensive cooperation agreement between the two parties. To implement the China-New Zealand science and technology cooperation agreements, the Ministry of Science and Technology approved the establishment of the "China-New Zealand International Joint Research Center for Biomedicine and Health" in 2015.

The Joint Laboratory is an extension and continuation of the "China-New Zealand International Joint Research Center for Biomedicine and Health." The Joint Laboratory focuses on five key areas: stem cell and regenerative medicine research, biotherapy for cancer, treatment of metabolic diseases, drug development, and infectious disease prevention and control, conducting in-depth research and clinical translation in these fields.


2014

On November 11, the Guangdong Provincial Laboratory of Stem Cell and Regenerative Medicine built by the Chinese Academy of Sciences Guangzhou Institute of Biomedicine and Health was unveiled.

2017

On November 11, the Guangdong Provincial Laboratory of Stem Cell and Regenerative Medicine built by the Chinese Academy of Sciences Guangzhou Institute of Biomedicine and Health was unveiled.

2017

On November 11, the Guangdong Provincial Laboratory of Stem Cell and Regenerative Medicine built by the Chinese Academy of Sciences Guangzhou Institute of Biomedicine and Health was unveiled.

2017

On November 11, the Guangdong Provincial Laboratory of Stem Cell and Regenerative Medicine built by the Chinese Academy of Sciences Guangzhou Institute of Biomedicine and Health was unveiled.

2017
Acknowledging Support
  1. Joint laboratory is supported by National Key R&D Program of China, No. 2022YFE0210600
  2. International Partnership Program of The Chinese Academy of Sciences, No.188GJHZ2022015GC
  3. Guangdong Province Grant for Belt and Road Joint Laboratory, No. 2022B1212050004

As for New Zealand’s Part, joint laboratory is also supported by China-MWC Collaborative Research Program Grant, MBIE Partners Investment Grant MALA1901 and HRC Project Grant 19/816.

Contact

Name

Title

Email

SUN Fei

Director

sun_fei@gibh.ac.cn

CAI Chenleng

Deputy Director

cai_chenleng@gibh.ac.cn

LI Peng

Executive Deputy Director

li_peng@gibh.ac.cn

CHEN Chaonan

Committee member

chen_chaonan@gibh.ac.cn